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Abstract
Introduction: Ankylosing spondylitis (AS) is a familial, heritable disease specified by syndesmophyte formation
leading to an ankylosed spine. Endoplasmic reticulum aminopeptidase 1 (ERAP1) genetic variations have been
widely proved to be associated with AS in several ethnic populations. The aim of this study was to investigate
whether ERAP1 single nucleotide polymorphisms (SNPs) are associated with AS susceptibility and disease severity
in Taiwanese.
Methods: Four ERAP1 SNPs (rs27037, rs27980, rs27044 and rs30187) were genotyped in 797 Taiwanese AS patients
and 1,150 healthy controls. Distributions of genotype and alleles were compared between AS patients and healthy
controls, and among AS patients stratified by clinical parameters.
Results: The SNP rs27037T allele appeared to be a risk factor for AS susceptibility (P = 5.5 × 10
-5, OR 1.30, 95% CI:
1.15 to 1.48; GT+TT vs. GG P = 9.3 × 10
-5, OR 1.49, 95% CI: 1.22 to 1.82). In addition, the coding SNP (cSNP)
rs27044G allele (P = 1.5 × 10
-4, OR 1.28, 95% CI: 1.13 to 1.46; CG+GG vs. CC, P = 1.7 × 10
-3, OR 1.44, 95% CI: 1.15 to
1.81) and the cSNP rs30187T allele (P = 1.7 × 10
-3, OR 1.23, 95% CI: 1.08 to 1.40; CT+TT vs. CC P = 6.1 × 10
-3,O R
1.38, 95% CI: 1.10 to 1.74) were predisposing factors for AS. Notably, the rs27044G allele carriers (CG+GG vs. CC, P =
0.015, OR 1.59, 95% CI: 1.33 to 2.30) and rs30187T allele carriers (CT+TT vs. CC, P = 0.011, OR 1.63, 95% CI: 1.12 to
2.38) were susceptible to syndesmophyte formation in AS patients. Furthermore, two cSNPs (rs27044 and rs30187)
strongly associated with HLA-B27 positivity in AS patients. Finally, the ERAP1 SNP haplotype TCG (rs27037T/
rs27980C/rs27044G) is a major risk factor for AS (adjusted P <0.00001, OR 1.38, 95% CI: 1.12 to 1.58) in Taiwanese.
Conclusions: This study provides the first evidence of ERAP1 SNPs involving syndesmophyte formation. The
interactions between ERAP1 SNPs and HLA-B27 play critical roles in pMHC I pathway processing contributing to
the pathogenesis of AS in multiple populations.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory
arthritis that preferably affects the sacroiliac and spine
joints in young males. Chronic inflammation in joints
causes the alteration of joint architecture with new bone
formations, and joint fusions may occur consequently
[1,2]. The unique structural changes of syndesmophyte
formation and ankylosis of the vertebrae are the primary
causes of early severe work disability of AS patients dur-
ing disease progressions [1-4]. Multiple factors and com-
plex biological interactions may be involved in AS
development [5-8].
Twin and family studies revealed a substantial propor-
tion of heritability in AS susceptibility. Genetic studies
indicate that HLA-B27 in the MHC (major histocompat-
ibility complex) locus confers the greatest risk to AS
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any medium, provided the original work is properly cited.susceptibility. However, genome wide association studies
(GWAS) also reveal that the non-MHC genes contribute
to the AS disease process [4,5,8-10]. Several genes and
genetic regions have now been discovered and known to
be associated with AS susceptibility and severity [8-10].
Of note, there were conflicting association results
between Caucasians and Asians [9-12].
Endoplasmic reticulum aminopeptidase 1 (ERAP1)
(also known as aminopeptidase regulator of TNFR1
shedding 1 or ARTS1) is an important non-MHC gene
associated with AS in genetic studies [9,10]. Function-
ally, ERAP1 facilitates the antigen peptide loading onto
the major histocompatibility complex class I (MHC I)
through trimming the fragmented antigen peptides into
the optimal length for peptide/MHC I (pMHC I) com-
plex formation, which is necessary for effective immune
responses [13-17]. In addition, ERAP1 involves the shed-
ding of pro-inflammatory cytokine receptors for TNFa,
IL-1, and IL-6 [18-20]. ERAP1 SNPs are associated with
AS in several ethnic populations [9-12,21-26], but it is
unknown whether ERAP1 SNPs have a role in AS devel-
opment in Taiwanese. The aim of the present study was
to examine whether the ERAP1 SNPs are associated
with AS susceptibility and have effects on AS disease
severity of syndesmophyte development in Taiwanese.
Materials and methods
Study subjects
The present study recruited 797 patients who fulfilled
the 1984 revised New York diagnostic criteria for AS
[27], and were followed up at Chang Gung Memorial
Hospital (a 3,600-bed medical center and university hos-
pital). Radiographs of the cervical, thoracic and lumbar
s p i n ew e r eu s e db yr h e u m a t o l o g ys p e c i a l i s t st oe v a l u a t e
syndesmophyte formations according to modified
Stoke’s Ankylosing Spondylitis Spinal Score (mSASSS).
To ensure the accuracy of evaluation, two rheumatology
specialists (Chen and Ho) independently scored the syn-
densmophyte formations by blindly reading radiographs
of AS patients for appropriate inter- and intra-reader
reliability. The X-ray observations were further classified
into three groups: group 1 patients did not have any
syndesmophyte formations (mSASSS <3), group 2
patients had less than four fused syndesmophyte forma-
tions (mSASSS <24) and group 3 patients had four or
more syndesmophyte formations (mSASSS >24). The
rare disagreements of the radiograph-based evaluations
were resolved through consultations between two physi-
cians to eliminate any subjectivity. HLA-B27 antigen
positivity was determined by flow cytometry analysis
and/or PCR assays. In this study, a total of 1,150 healthy
normal controls (512 males and 638 females) were
recruited, following a questionnaire survey to exclude
donors with rheumatoid arthritis (RA), systemic lupus
erythematous (SLE), AS and autoimmune thyroiditis,
diabetes mellitus (DM), viral hepatitis (HBV and HCV)
infections and cardiovascular diseases. The age of
healthy control donors ranged from 18 to 64 years-old
with a mean age of 40.3 ± 10.7. The local ethics com-
mittee of Chang Gung Memorial Hospital approved the
present study. Informed consent was obtained from all
patients
Nucleic acid isolation
Anti-coagulated peripheral blood was obtained from
healthy control donors and AS patients. Genomic DNA
was isolated from EDTA anti-coagulated peripheral
blood using the Puregene DNA isolation kit (Gentra
Systems, Minneapolis, MN, USA) as previously
described [28].
TaqMan-based assays for ERAP1 SNPs
ERAP1 SNPs were genotyped with the TaqMan SNP
Made to Order Assays from Applied Biosystems (ABI,
Foster City, CA, USA). ERAP1 genotypes were deter-
mined using ABI TaqMan Genotyper software according
to the vendor’s instruction (Foster City, CA, USA).
Statistical analysis
We carried out single-locus ERAP1 SNP analyses in 797
AS patients and 1,150 normal, healthy controls. Three
chi-square tests (the genotype test, the allele test and
Cochran-Armitage trend test) were performed. Associa-
t i o n so fS N P sw i t hA S( P <0.05) were identified using
Plink [29] and the SAS/Genetics software package
release 8.2 (SAS Institute, Cary, NC, USA). For the ana-
lysis of risk genotypes/alleles, logistic regression models
adjusted for sex were used to calculate P-values, odds
ratios (ORs) and their 95% confidence intervals. Linkage
disequilibrium (LD) between marker loci was assessed
and haplotype blocks were constructed using Haploview
4.1(Broad Institute of MIT, Cambridge, MA, USA). For
each haplotype combination estimated, the haplotype-
trait association was tested within different subgroups of
disease status (case vs. control), HLA B27 positivity, and
syndesmophyte formation were tested for the haplotype-
trait association using the SAS HAPLOTYPE procedure.
To investigate the association of SNPs with clinical
characteristics, we controlled for each of clinical charac-
teristics and performed logistic regression analyses. The
5% level of significance (P <0.05) was adopted for all the
analyses. To account for the confounding effects
between HLA-B27 positivity and syndesmophyte, we
performed the stratified analysis with Cochran -Mantel
-Haenszel (CMH) tests for ERAP1 SNP and syndesmo-
phyte formation associations, controlling for HLA-B27
positivity. The results of the trend test, genotype and
allelic analyses were adjusted for HLA-B27 positivity.
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SNP and HLA-B27 associations, adjusted by syndesmo-
phytes formation. The P-values, ORs and 95% CIs for
the trend test, genotype and allelic analyses adjusted for
syndesmophyte formation.
Results
Clinical characteristics of AS study cohort
The present study recruited 797 Taiwanese AS patients
(667 males and 130 females). The onset ages of 697 AS
patients ranged from 5 to 60 years-old. The onset age of
a single female was 72 years-old. We were unable to
identify exact onset ages of the other 99 AS patients in
the study. Among AS patients, 739 (92.7%) patients
were HLA-B27 carriers and 393 patients demonstrated
syndesmophyte formation (group 2 with mSASSS <24
plus group 3 with mSASSS >24) based on spine radio-
graph data. Syndesmophyte formation was significantly
more common in AS patients positive for HLA-B27
(380 out of 739, 51.4%) as compared to AS patients
negative for HLA-B27 (13 of 58, 22.4%) (P <0.0001, OR
3 . 6 6 ,9 5 %C I :1 . 9 4t o6 . 9 1 ) .S y n d e s m o p h y t ef o r m a t i o n
was also significantly enriched in male AS patients (55%,
367 of 667) as compared to the female AS patients
(20%, 26 of 130) (P <0.0001, OR 4.89, 95% CI: 3.10 to
7.72). Thus, HLA-B27 positivity and male gender were
two major risk factors for AS syndesmophyte formation
in our cohort. As shown in Table 1, most AS patients in
this cohort had long disease courses (≥5 years) whereas
patients with longer disease durations (>20 years) were
enriched in AS with the syndesmophyte formation
group (54.5%), indicating that the disease duration is
also a risk factor for syndesmophyte formation.
Association of ERAP1 SNPs with AS
Four ERAP1 SNPs (rs27037, rs27980, rs27044 and
rs30187) were selected based on the SNP locations
(chromosome position, coding and regulatory regions)
and their functional relevance described in the previous
studies. Those four SNPs were genotyped in 797 AS
patients and 1,150 healthy controls. The distributions of
ERAP1 SNP genotypes were conformed to the Hardy-
Weinberg equilibrium in the genotyped subjects (P
>0.05). As shown in Table 2, significant differences in
the distributions of ERAP1 SNP genotypes and alleles
were observed between AS patients and the normal
healthy controls. Our analyses indicate that the SNP
rs27037T allele is a risk factor for AS susceptibility
(Trend test P =4×1 0
-5 with 100,000 permutations; T
vs. G, P =5 . 5×1 0
-5, OR 1.30, 95% CI: 1.15 to 1.48;
genotypes GT+TT vs. GG, P =9 . 3×1 0
-5, OR 1.49, 95%
CI: 1.22 to 1.82). On the other hand, the SNP rs27980C
allele appears to be a modest risk factor for AS suscept-
ibility (Trend test P = 0.035 with 100,000 permutations;
C vs. A, P = 0.033, OR 1.15, 95% CI: 1.01 to 1.31; geno-
type AC+CC vs. AA, P = 0.024, OR 1.31; 95% CI: 1.04
to 1.65). In addition, both cSNP (coding SNP) rs27044G
allele (Trend test P =1 . 7×1 0
-4 with 100,000 permuta-
tions; G vs. C, P =1 . 5×1 0
-4, OR 1.28, 95% CI: 1.13 to
1.46; genotypes CG+GG vs. CC, P =1 . 7×1 0
-3,O R
1.44, 95% CI: 1.15 to 1.81), and the cSNP rs30187T
allele (Trend test P =1 . 6×1 0
-3 with 100,000 permuta-
tions. T vs. C, P =1 . 7×1 0
-3, OR 1.23, 95% CI: 1.08 to
1.40; genotype CT+TT vs. CC, P =6 . 1×1 0
-3,O R1 . 3 8 ,
95% CI: 1.10 to 1.74) are risk factors for AS
susceptibility.
Association of ERAP1 SNPs with AS clinical parameters
AS is a heterogeneous chronic inflammatory disease and
present with diverse clinical severity. Subsequently, we
stratified AS patients according to clinical characteristics
and analyzed the genetic data. As shown in Table 3, we
observed that the cSNP rs27044G allele carriers (geno-
type CG+GG vs. CC, P = 0.015, OR 1.59, 95% CI: 1.33
to 2.30) and the cSNP rs30187T allele carriers (geno-
type CT+TT vs. CC, P = 0.011, OR 1.63, 95% CI: 1.12
to 2.38) are susceptible to syndesmophyte formation in
AS patients. After adjusting for the effect of HLA-B27
positivity, the cSNP rs30187 remains significantly asso-
ciated with syndesmophyte formation (CMH statistics =
4.236, degree of freedom = 1, P = 0.040) while cSNP
rs27044 is marginally associated with syndesmophyte
formation (CMH statistics = 3.843, degree of freedom =
1, P = 0.050). The remaining two SNPs did not show
any significant associations. Because previous studies
demonstrated that human leukocyte antigen HLA-B27
has a causative role in AS pathogenesis, we subse-
quently investigated whether there is interaction
between the ERAP1 SNPs and HLA-B27 positivity. We
observed that the distributions of genotypes of four
ERAP1 SNPs revealed significant differences between
AS patients positive for HLA-B27 and patients negative
for HLA-B27 (Table 4). As shown in Table 4, allele dis-
tributions of three ERAP1 SNPs (rs27037, rs27044, and
rs30187) were significantly different between AS
patients positive for HLA-B27 and the patient negative
for HLA-B27. Notably, two cSNPs (rs27044 and
rs30187) are strongly associated with HLA-B27 positiv-
ity. The cSNP rs27044G allele was significantly enriched
in AS patients positive for HLA-B27 (Trend test P = 6.3
×1 0
-3 with 100,000 permutations; G vs. C, P =5 . 8×
10
-3, OR 1.70, 95% CI: 1.16 to 2.49; genotypes CG+GG
vs. CC, P =7×1 0
-4,O R2 . 7 1 ,9 5 %C I :1 . 5 3t o4 . 8 2 ) .
The cSNP rs30187T allele was also significantly
enriched in AS patients positive for HLA-B27 (Trend
test P =6 . 1×1 0
-3 with 100,000 permutations; T vs. C,
P = 5.4 × 10
-3, OR 1.71, 95% CI: 1.17 to 2.49; genotypes
CT+TT vs. CC, P =4×1 0
-4, OR 2.86, 95% CI: 1.61 to
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SNPs and HLA-B27 positivity after controlling for the
syndesmophyte formation. The CMH test results
revealed that the significant associations between three
ERAP1 SNPs (rs27037, rs27044, and rs30187) and HLA-
B27 positivity (P <0.01). Our data indicate that interac-
tion of ERAP1 and HLA-B27 may play a pivotal role in
the pathogeneses of AS.
ERAP 1 SNP haplotypes are associated with AS
susceptibility
We next examined the influence of ERAP1 SNP haplo-
types on AS susceptibility and syndesmophyte formation
according to the linkage disequilibrium (LD) block (Fig-
ure 1). Due to the fact that two ERAP1 cSNPs (rs27044
and rs30187) are in extremely strong LD (0.99), we
selected rs27044 as the representative marker for two
Table 1 The demographic and clinical characteristics of AS patients positive and negative for sydesmophyte
Clinical characteristic AS
N = 797 (%)
Sydesmophyte positive
N = 393 (%)
Sydesmophyte negative
N = 404 (%)
Gender (female)
130 (16.3%) 26 (15.1%) 104 (25.7%)
Age at onset
≤16 117 (14.7%) 55 (14.0%) 62 (15.4%)
17 to 40 533 (66.9%) 274 (69.7%) 259 (64.1%)
41 to 60 47 (5.9%) 12 (3.1%) 35 (8.7%)
>60 1 (0.1%) 0 (0%) 1 (0.2%)
Undetermined 99 (12.4%) 52 (13.2%) 47 (11.6%)
Disease duration
<5 years 20 (2.5%) 4 (1.0%) 16 (4.0%)
5 to 10 years 118 (14.8%) 17 (4.3%) 101 (25.0%)
11 to 15 years 134 (16.8%) 54 (13.8%) 80 (19.8%)
16 to 20 years 125(15.7%) 52 (13.2%) 73 (18.1%)
>20 years 301 (37.8%) 214 (54.5%) 87 (21.5%)
Undetermined 99 (12.4%) 52 (13.2%) 47 (11.6%)
HLA-B27 positivity
739 (92.7%) 380 (96.7%) 359 (88.9%)
Baseline mSASSS at evaluati on
mSASSS <3 404 (50.7%)
mSASSS <24 120 (15.0%)
mSASSS ≤24 273 (34.3%)
Sydesmophyte positive: AS patients with syndesmophyte formations (N = 393; mSASSS <24 plus mSASSS ≤24). Sydesmophyte negative, AS patients without
syndesmophyte formations (N = 404; mSASSS <3)
mSASSS, modified Stoke’s Ankylosing Spondylitis Spinal Score
Table 2 ERAP1 SNP analyses in Taiwanese AS patients and normal controls
SNP
/Group
RA
/RAF
Genotype
/Frequency
Trend test
P*
Genotype analysis Allelic analysis
P OR (95% CI) P OR (95% CI)
rs27037 T GG GT TT GT + TT vs. GG T vs. G
Normal (N = 1150) 0.415 0.341 0.488 0.171 4 × 10
-5 9.3 × 10
-5 1.49 (1.22-1.82) 5.5 × 10
-5 1.30 (1.15-1.48)
AS (N = 796) 0.481 0.258 0.524 0.219
rs27980 C AA AC CC AC + CC vs. AA C vs. A
Normal (N = 1150) 0.538 0.215 0.494 0.291 0.035 0.024 1.31 (1.04-1.65) 0.033 1.15 (1.01-1.31)
AS (N = 797) 0.573 0.173 0.508 0.319
rs27044 G CC CG GG CG + GG vs. CC G vs. C
Normal (N = 1149) 0.509 0.235 0.513 0.252 1.7 × 10
-4 1.7 × 10
-3 1.44 (1.15-1.81) 1.5 × 10
-4 1.28 (1.13-1.46)
AS (N = 796) 0.570 0.176 0.508 0.317
rs30187 T CC CT TT CT + TT vs. CC T vs. C
Normal (N = 1150) 0.529 0.220 0.503 0.277 1.6 × 10
-3 6.1 × 10
-3 1.38 (1.10-1.74) 1.7 × 10
-3 1.23 (1.08-1.40)
AS (N = 797) 0.580 0.169 0.502 0.329
RA: Risk allele. RAF: Risk allele frequency. * The Trend test p-values were generated from 100,000 permutations.
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in Table 5, ERAP1 SNP haplotype TCG (rs27037T/
rs27980C/rs27044G) frequency is significantly increased
in AS patients (0.475) as compared to healthy controls
(0.399) (adjusted P <0.00001, OR 1.38, 95% CI: 1.12 to
1.58), suggesting that the haplotype TCG is a risk mar-
ker for AS. On the other hand, haplotype GCC
(rs27037G/rs27980C/rs27044C) frequency was
Table 3 ERAP1 SNP analyses in normal controls and AS patients positive and negative for syndesmophyte
SNP
/Group
RA
/RAF
Genotype
/Frequency
Trend test
P**
Genotype analysis Allelic analysis
P OR (95% CI) P OR (95% CI)
rs27037 T GG GT TT GT + TT vs. GG T vs. G
Normal (N = 1150) 0.415 0.341 0.488 0.171 7 × 10
-5 2×1 0
-4 1.64 (1.27-2.14) 7.8 × 10
-5 1.39 (1.18-1.63)
AS Syn+ (N = 393) 0.496 0.239 0.529 0.232
AS Syn- (N = 403) 0.465 0.275 0.519 0.206 0.215 0.243 1.21 (0.88-1.66) 0.217 1.13 (0.93-1.38)
Adjusted for HLA-B27+* 0.338 0.449 1.13 (0.82-1.57) 0.351 1.10 (0.90-1.34)
rs27980 C AA AC CC AC + CC vs. AA C vs. A
Normal (N = 1150) 0.538 0.215 0.493 0.291 9.9 × 10
-3 0.011 1.49 (1.10-2.02) 9.4 × 10
-3 1.24 (1.05-1.46)
AS Syn+ (N = 393) 0.592 0.155 0.506 0.338
AS Syn- (N = 404) 0.555 0.191 0.510 0.300 0.134 0.188 1.28 (0.89-1.85) 0.134 1.16 (0.95-1.42)
Adjusted for HLA-B27+ 0191 0.311 1.21 (0.83-1.77) 0.195 1.14 (0.93-1.40)
rs27044 G CC CG GG CG + GG vs. CC G vs. C
Normal (N = 1149) 0.509 0.235 0.513 0.252 7 × 10
-5 10
-4 1.85 (1.35-2.53) 9.8 × 10
-5 1.38 (1.18-1.63)
AS Syn+ (N = 393) 0.589 0.143 0.537 0.321
AS Syn-(N = 403) 0.552 0.208 0.479 0.313 0.136 0.015 1.59 (1.33-2.30) 0.136 1.16 (0.95-1.42)
Adjusted for HLA-B27+ 0.271 0.050 1.46 (1.00-2.13) 0.277 1.12 (0.91-1.37)
rs30187 T CC CT TT CT + TT vs. CC T vs. C
Normal (N = 1150) 0.529 0.220 0.503 0.277 1.3 × 10
-3 3×1 0
-4 1.81 (1.31-2.50) 1.5 × 10
-3 1.31 (1.11-1.54)
AS Syn+ (N = 393) 0.594 0.135 0.542 0.323
AS Syn-(N = 404) 0.566 0.203 0.463 0.334 0.258 0.011 1.63 (1.12-2.38) 0.248 1.12 (0.92-1.37)
Adjusted for HLA-B27+ 0.463 0.040 1.50 (1.02-2.20) 0.456 1.08 (0.88-1.32)
RA: Risk allele. RAF: Risk allele frequency. The case-control association tests were performed in two subsets of the samples: (1) AS patients with syndesmophyte
(AS Syn+) vs. normal controls; (2) AS patients with syndesmophyte (AS Syn+) vs. AS patients without syndesmophyte (AS Syn-). *Cochran -Mantel -Haenszel
(CMH) tests for ERAP1 SNP and syndesmophyte associations, controlling for HLA-B27 positivity. ** The Trend test p-values were generated from 100,000
permutations.
Table 4 ERAP1 SNP analyses in normal controls and AS patients positive and negative for HLA-B27
SNP
/Group
RA
/RAF
Genotype
/Frequency
Trend test P** P Genotype analysis
OR (95% CI)
P Allelic analysis
OR (95% CI)
rs27037 T GG GT TT GT + TT vs. GG T vs. G
HLA-B27 + (N = 738) 0.488 0.245 0.534 0.221 0.042 5.6 × 10
-3 2.17 (1.26-3.76) 0.038 1.50 (1.02-2.21)
HLA-B27 - (N = 58) 0.388 0.414 0.397 0.190
Adjusted for syndesmophyte+* 0.057 9.1 × 10
-3 2.10 (1.20-3.66) 0.056 1.46(0.99-2.16)
rs27980 C AA AC CC AC + CC vs. AA C vs. A
HLA-B27 + (N = 739) 0.578 0.165 0.514 0.321 0.172 0.034 1.93 (1.05-3.54) 0.147 1.32 (0.91-1.93)
HLA-B27 - (N = 58) 0.509 0.276 0.431 0.293
Adjusted for syndesmophyte+ 0.229 0.056 1.61 (0.99-3.38) 0.217 1.27 (0.87-1.86)
rs27044 G CC CG GG CG + GG vs. CC G vs. C
HLA-B27 + (N = 738) 0.580 0.163 0.515 0.323 6.3 × 10
-3 7×1 0
-4 2.71 (1.53-4.82) 5.8 × 10
-3 1.70 (1.16-2.49)
HLA-B27 - (N = 58) 0.448 0.345 0.414 0.241
Adjusted for syndesmophyte+ 0.010 2.7 × 10
-3 2.45 (1.36-4.39) 0.011 1.64 (1.12-2.42)
rs30187 T CC CT TT CT + TT vs. CC T vs. C
HLA-B27 + (N = 739) 0.589 0.156 0.510 0.334 6.1 × 10
-3 4×1 0
-4 2.86 (1.61-5.09) 5.4 × 10
-3 1.71 (1.17-2.49)
HLA-B27 - (N = 58) 0.457 0.345 0.397 0.259
Adjusted for syndesmophyte+ 0.011 1.6 × 10
-3 2.56 (1.43-4.61) 8.5 × 10
-3 1.67 (1.14-2.45)
RA: Risk allele. RAF: Risk allele frequency. * Cochran -Mantel -Haenszel tests for ERAP1 SNP and HLA-B27 associations, adjusted by syndesmophyte formation. **
The Trend test p-values were generated from 100,000 permutations. Sydesmophyte +: syndesmophyte formation positive
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pared to AS patients (0.085) (adjusted P =1 . 9×1 0
-3,
OR 0.69, 95% CI: 0.55 to .87), indicating that the haplo-
type GCC has a protective role against AS. The haplo-
type TCG frequency is slightly higher in AS patients
positive for syndesmophyte formation as compared to
that in AS patients negative for syndesmophyte forma-
tion; however, no significant difference was observed (P
>0.05)
Discussion
Complex interactions between environmental factors
and host immune responses are the origins for AS
development [4,5]. It is clear that genetic factors influ-
ence the immune responses and progression of AS. The
current study demonstrated the associations of EARP1
SNPs with the AS susceptibility in Taiwanese. Amino-
peptidases play a central role in the generation of MHC
class I-binding peptides through processing and trim-
ming peptide. As an IFNg-induced aminopeptidase,
ERAP1 breaks down protein antigen precursors and
trims the peptides fragments into the suitable length for
peptide/MHC I complex formation in ER [13,14,30]. In
mice, ERAP1 deficiency led to the reduced MHC I
expression in splenocytes and the decreased viral pep-
tide presentation by MHC I on fibroblasts [31]. The
generation of effective CD8 T cell responses was com-
promised in ERAP1 deficient mice as self and foreign
antigen presentations were disrupted [31-36]. In
humans, over-expression of ERAP1 was observed in AS
patient dendritic cells (DCs) [37]. ERAP1 also enhances
phagocytic activity of human macrophages through gen-
erating active peptides [38]. Functionally, ERAP1 may
have a substantial role in the AS pathogenesis. Our cur-
rent study demonstrated the associations of ERAP1
SNPs with the AS susceptibility in Taiwanese, indicating
that ERAP1 has a role in AS development in Taiwanese
We observed that >90% of AS patients are HLA-B27
carriers. Our data confirmed that HLA-B27 plays the
most critical role in AS disease progression. HLA-B27
may influence AS development through three possible
mechanisms: I) HLA-B27 may preferentially bind dis-
tinctive arthritogenic peptides, II) inappropriately folded
HLA-B27 heavy chain without a docking antigen peptide
may lead to the unfolded protein responses (UPRs), and
III) HLA-B27 may have a tendency to be expressed as
empty MHC I heavy chain homodimers [4,39]. However,
the precise mechanisms underlying the critical role of
HLA-B27 in AS development remain to be elucidated
[40].
Of great importance, immune surveillance of the CD8
T cell to environmental insults, such as bacterial and
Figure 1 Pairwise linkage disequilibrium (LD) plot patterns for four polymorphisms through ERAP1 regions on chromosome 5.( a:
controls N = 1,150; b: AS cases N = 797; c: Totals N = 1,947).
Table 5 Haplotype analysis of ERAP 1 SNPs in 797 AS patients and 1150 normal controls.
Associated haplotypes Frequency EM algorithm* Logistic regression Logistic regression
(rs27037 + rs27980 + rs27044) AS Normal P -value P -value OR (95% CI) (sex adjusted)
P -value OR (95% CI)
GCC 0.085 0.119 9 × 10
-3 7×1 0
-4 0.69 (0.55-0.85) 1.9 × 10
-3 0.69 (0.55-0.87)
TAG 0.008 0.012 2.6 × 10
-3 3.9 × 10
-3 0.21 (0.07-0.61) 4.3 × 10
-3 0.21 (0.07-0.61)
TCG 0.475 0.399 <0.00001 <0.00001 1.36 (1.12-1.55) <0.00001 1.38 (1.12-1.58)
*The p-values for the estimated haplotypes were generated from 10,000 permutations.
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Page 6 of 10viral infections, requires the interaction between T cell
receptor (TCR) and peptide/MHC I complex. ERAP1
trims protein antigens to fit for MHC I including HLA-
B27. The stability of antigen peptide/MHC I complexes
is influenced by both ERAP1 activities and peptide bind-
ing groove sequences of MHC I [41]. Very recently,
Evans et al. demonstrated the gene-gene interaction
between ERAP1 SNP rs30187T allele and HLA-B27
positivity in the pathogenesis of AS [42]. Our study pro-
vided further evidence that ERAP1 SNPs are indeed
associated with the HLA-B27 positivity in Taiwanese AS
patients. Our data support the notion that ERAP1 and
HLA-B27 have synergistic roles in AS pathogenesis in
humans. Our findings also suggest that abnormal anti-
gen processing by ERAP1 and antigen presentation by
HLA-B27 may be critical pathways in AS development.
On the other hand, AS patients negative for HLA-B27
may develop pathologic immune responses through the
other unidentified biological pathways.
The disease course of AS is heterogeneous and the
genetic factors are believed to influence disease suscept-
ibility and severity. Early syndesmophyte formations in
AS patients indicate radiologic progression and charac-
teristic structure changes that lead to the decreased
spinal mobility, functional impairments and work dis-
ability in long-term disease courses [4,43]. Sacroiliac
joint biopsy examinations frequently revealed significant
new bone formations and bony ankylosis in AS patients
[44]. Spinal inflammation and bone remodeling may be
two important factors in the progress of ankylosis but
the precise pathogenesis of AS remains unknown
[44,45]. The current study demonstrated that ERAP1
cSNPs rs27044 and rs30187 are modestly associated
with AS syndesmophyte formation, suggesting that the
ERAP1 cSNPs may affect AS disease severity. Syndesmo-
phyte of AS is more likely to develop at sites of previous
inflammation, indicating ankylosis development is
strongly correlated with inflammation [44]. The ERAP1
protein also participates in the regulation of proinflam-
matory cytokine receptor functions. ERAP1 cleaves
membrane-associated TNFR1, IL-6R, and interleukin 1
receptor II (IL-1RII) and causes the shedding of those
cytokine receptors. Some cellular and molecular signal
pathways that regulate the development of hematopoie-
tic cell and bone homeostasis are shared by the immune
system and bone development [45]. IL6 and TNFa cyto-
kine networks may affect the Th17 cell development
and the plasticity of T cell differentiation, which are cri-
tical in the pathogenesis of AS. The serum cytokine
receptor levels in AS patients are correlated with the
levels ESR and CRP, which are indicators of AS inflam-
matory activities. Nevertheless, the serum cytokine
receptor levels in patients with AS are not influenced by
ERAP1 SNPs [46]. Animal models have even suggested
that inflammation and new bone formation are
uncoupled processes [47,48]. Clinically, various anti-
TNF therapies suppress the inflammation process but
do not retard the structural progression according to
modified Stoke’s Ankylosing Spondylitis Spinal Score
(mSASSS) [49-51]. These findings indicate the syndes-
mophyte development may largely attribute to the
intrinsic genetic effects of ERAP 1 on p/MHC I complex
formation.
UPRs can cause the activation of NFB, which could
enhance downstream proinflammatory gene expression
and promote inflammations. Genetic variations of HLA-
B27 and ERAP1 have functional roles in the misfolding
and UPR of the heavy chain [4,40]. HLA-B27 misfolding
is triggered in the oxidizing environment in endoplasmic
reticulum (ER) by exposing cysteine residues within the
heavy chain [40]. ERAP1 is required for efficient enzy-
matic activities that suggest the polymorphisms at sites
remote from the catalytic sites might modify this asso-
ciation [52]. ERAP1 processes peptide substrates with
the optimal sizes for MHC I (40, 41). Crystallography
analyses suggest that the coding SNP rs30187 changes
the amino acid residue that may affect the catalytic
activity [53]. Notably, the alleles and genotypes of
ERAP1 SNPs in Taiwanese and other Asians showed
different distribution and opposite risk results in AS
susceptibility compared to Caucasians [9-12,21-26]. In
addition, ERAP1 SNP rs30187C allele carriers (CC+CT)
were found to be associated with higher baseline radio-
graphic severity based on mSASSS on univariate analysis
[54]. The current study demonstrated that both SNP
rs30187T and rs27044G allele carrier were modestly
associated with AS disease severity of syndesmophyte
formation. Functional studies of ERAP1 SNPs have iden-
tified that the rs30187C allele carries less biological
enzyme activity, which may decrease aberrant peptide
processing and HLA-B27 presentation [42], the
rs27044C allele carrier genotype demonstrated signifi-
cantly higher free heavy chain (FHC) expression but
lower intact HLAB27 complexes/FHCs ratio [55], and
ERAP1 SNPs (rs30187 and rs27044) showed specific
peptide substrate sequence interaction [52]. Moreover,
large multifunctional peptidase 2 (LMP2) rs17587 SNP
has been demonstrated to associate with AS radio-
graphic severity [54]. These findings indicated multiple
gene interactions are involved in the complexity of AS
disease susceptibility and severity, and no definite func-
tional roles of ERAP1 cSNPs rs30187 and rs27044 in
antigen processing can fully answer the discrepancy
results in different ethnic backgrounds. Nevertheless,
other ERAP1 SNPs may also affect UPR and subsequent
immune responses. Further functional studies are
required to understand the precise roles of ERAP1 SNPs
contribute to the AS pathogenesis.
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Page 7 of 10In this cross sectional study, some AS patients may
not receive enough follow-up in the syndesmophyte for-
mation assessment, which is the main limitation of our
study. Therefore, future longitudinal studies are required
to estimate the effect of ERAP1 SNPs on the bamboo
spine development in large AS patient cohorts.
Conclusion
This study provided further evidence that ERAP1 inter-
action with HLA-B27 is involved in the development of
AS and disease severity, which emphasized the critical
role of pMHC I pathway genes in the pathogenesis of
AS. Identification of the functional causal alleles of
ERAP1 provides a new avenue in understanding the
molecular mechanisms of ASp a t h o g e n e s i s ,w h i c hm a y
lead to novel treatment approaches.
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